Home Cart Sign in  
Chemical Structure| 1097917-15-1 Chemical Structure| 1097917-15-1

Structure of ASP3026
CAS No.: 1097917-15-1

Chemical Structure| 1097917-15-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ASP3026 is a selective inhibitor for ALK with IC50 of 3.5 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ASP3026

CAS No. :1097917-15-1
Formula : C29H40N8O3S
M.W : 580.74
SMILES Code : O=S(C1=CC=CC=C1NC2=NC=NC(NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3OC)=N2)(C(C)C)=O
MDL No. :MFCD21609265
InChI Key :MGGBYMDAPCCKCT-UHFFFAOYSA-N
Pubchem ID :25134326

Safety of ASP3026

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ASP3026

RTK

Isoform Comparison

Biological Activity

Description
ASP3026 is a potent, selective, and orally administered inhibitor of anaplastic lymphoma kinase (ALK). It promotes apoptosis in tumor cells and is applicable in non-small cell lung cancer (NSCLC) research[1][2].
Target
  • ALK

    ALK, IC50:3.5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
H2228 cells 64.8 nM Evaluate the inhibitory effect of ASP3026 on ALK PMC4215402
NPM-ALK+ ALCL cell lines (Karpas 299, SU-DHL-1, SUP-M2, SR-786, DEL) 0.1, 0.5, 1.0, 1.5, 2.5, 3.0 µM 48 and 72 hours To evaluate the effect of ASP3026 on the viability of NPM-ALK+ ALCL cells. Results showed that ASP3026 significantly reduced the viability of all tested cell lines at 48 and 72 hours, with varying IC50 values across cell lines. PMC4170597
Ba/F3 NPM-ALK S1206Y 0.110 µmol/L 72 hours Evaluate the inhibitory activity of ASP3026 on NPM-ALK S1206Y mutant cells, IC50 was 0.110 µmol/L, showing sensitivity. PMC4529334
Ba/F3 NPM-ALK G1269A 0.364 µmol/L 72 hours Evaluate the inhibitory activity of ASP3026 on NPM-ALK G1269A mutant cells, IC50 was 0.364 µmol/L, showing resistance. PMC4529334
Ba/F3 NPM-ALK G1202R 1.177 µmol/L 72 hours Evaluate the inhibitory activity of ASP3026 on NPM-ALK G1202R mutant cells, IC50 was 1.177 µmol/L, showing high resistance. PMC4529334
Ba/F3 NPM-ALK L1152R 2.763 µmol/L 72 hours Evaluate the inhibitory activity of ASP3026 on NPM-ALK L1152R mutant cells, IC50 was 2.763 µmol/L, showing high resistance. PMC4529334
Ba/F3 NPM-ALK L1196M 0.682 µmol/L 72 hours Evaluate the inhibitory activity of ASP3026 on NPM-ALK L1196M mutant cells, IC50 was 0.682 µmol/L, showing resistance. PMC4529334
Ba/F3 NPM-ALK C1156Y 0.284 µmol/L 72 hours Evaluate the inhibitory activity of ASP3026 on NPM-ALK C1156Y mutant cells, IC50 was 0.284 µmol/L, showing moderate resistance. PMC4529334
Ba/F3 NPM-ALK WT 0.084 µmol/L 72 hours Evaluate the inhibitory activity of ASP3026 on NPM-ALK WT cells, IC50 was 0.084 µmol/L. PMC4529334
Human hepatocyte carcinoma HepG2 cells 0-300 μM 72 hours To assess the cytotoxicity of ASP3026 analogues, compound 36 showed low toxicity. PMC11189516
Plasmodium falciparum 3D7 parasites 10 μM 72 hours To evaluate the inhibitory effects of ASP3026 analogues on Plasmodium growth, compound 36 showed the most potent inhibition with an EC50 value of 736 nM. PMC11189516
Plasmodium falciparum 3D7 5.61 ± 0.26 µM 72 hours To evaluate the inhibitory effect of ASP3026 on Plasmodium growth, results showed that ASP3026 effectively inhibited Plasmodium growth. PMC7672456

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID Beige mice Crizotinib-resistant PDX mouse model Oral 100 mg/kg/day Once daily for approximately 2 weeks Evaluate the effect of ASP3026 on tumor growth in crizotinib-resistant PDX mice, results showed significant tumor growth inhibition PMC11416680
C.B-17 SCID mice Systemic xenograft lymphoma model Oral gavage 30 mg/kg Daily administration for 10 weeks (uninterrupted group) or 2 weeks followed by 4 weeks interruption and then 4 weeks continuation (interrupted group) To evaluate the inhibitory effect of ASP3026 on systemic NPM-ALK+ ALCL growth. Results showed that mice in the uninterrupted group achieved complete remission with no relapse or lymphoma-related death, while mice in the interrupted group experienced rapid relapse after discontinuation but showed significant tumor regression upon resumption of treatment. PMC4170597

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01284192 Advanced Malignancies|Positive... More >> for Anaplastic Lymphoma Kinase|Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS|Solid Tumor|B-Cell Lymphoma Less << PHASE1 COMPLETED 2025-03-16 Site US160, Orange, California... More >>, 92868, United States|Site US184, Sacramento, California, 95817, United States|Site US11, Chicago, Illinois, 60637, United States|Site US2688, Detroit, Michigan, 48201, United States|Site US2492, Houston, Texas, 77030, United States|Site US1905, San Antonio, Texas, 78229, United States Less <<
NCT01401504 Solid Tumor PHASE1 COMPLETED 2025-01-14 Kansai, Japan

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.61mL

1.72mL

0.86mL

17.22mL

3.44mL

1.72mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories